Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
This page is not indexed by search engines while we improve data quality.
Wang Yanfeng — Human Necessities
Wang Yanfeng holds 4 patents in Human Necessities, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Wang Yanfeng |
| Technology | Human Necessities |
| Patents in slice | 4 |
| Recent patents in slice | 0 |
| First year | 2016 |
| Last year | 2017 |
Representative patents
Notable publications linking Wang Yanfeng to Human Necessities.
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Recent filings
Latest patents from Wang Yanfeng in Human Necessities.
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US-9763944-B2 · Sep 19, 2017 · US
Related pages
Navigate to parent entity pages.